| Outcome Measures: |
Primary: Mean Percent Change From Baseline in Body Weight, Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Percentage of Participants Who Achieve ≥5% Body Weight Reduction, Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis., Week 52 | Secondary: Mean Change From Baseline in Body Weight, Mean Change from Baseline in Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 20|Percentage of Participants Who Achieve ≥10% Body Weight Reduction, Percentage of Participants who Achieve ≥10% Body Weight Reduction. A logistic regression model was used for this analysis., Week 52|Percentage of Participants Who Achieve ≥15% Body Weight Reduction, Percentage of Participants who Achieve ≥15% Body Weight Reduction. A logistic regression model was used for this analysis., Week 52|Mean Change From Baseline in Waist Circumference, Mean Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Absolute Body Weight, Mean Change from Baseline in Absolute Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Body Mass Index (BMI), Mean Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Hemoglobin A1c (HbA1c), Mean Change from Baseline in HbA1c. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Fasting Glucose (FSG), Mean Change from Baseline in FSG. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score, The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score, The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model with Variable = Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model using log (Actual measurement/Baseline) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52|Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg), LS mean was determined using MMRM model with log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables., Baseline, Week 52
|
| Locations: |
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, 102202, China|The First Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, 400016, China|Zhujiang Hospital, Guangzhou, Guangdong, 510280, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518039, China|The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan, 471003, China|The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, China|The First Affiliated Hospital of Nanhua University, Hengyang, Hunan, 421001, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, 213000, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210011, China|Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing, Jiangsu, 211100, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China|Wuxi People's Hospital, Wuxi, Jiangsu, 214023, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Siping Central People's Hospital, Siping, Jilin, 136000, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China|Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, 200040, China|Shanghai Hospital of Traditional Chinese Medicine, Shanghai, Shanghai, 200071, China|Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 201700, China|The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shanxi, 710077, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China|The First People's Hospital of Hangzhou, Hangzhou, Zhejiang, 310006, China|Huzhou Central Hospital, Huzhou, Zhejiang, 313000, China|Ningbo First Hospital, Ningbo, Zhejiang, 315010, China|The Fifth People's Hospital of Shanghai, Shanghai, 200240, China|Shanghai Minhang District Central Hospital, Shanghai, 201199, China
|
